Your session is about to expire
← Back to Search
Allogeneic adipose derived mesenchymal stem cells for Ischemia Reperfusion Injury
Study Summary
This trial will test if the investigational drug aMSCs can help treat IRI, a condition that can occur after a kidney transplant.
- Ischemia Reperfusion Injury
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Intra-arterial infusion
- Group 2: Intra parenchymal injection & Intra-arterial infusion
- Group 3: Intra parenchymal injection
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are researchers still accepting new participants for this experiment?
"According to the clinicaltrials.gov database, this experiment has been open for signups since September 28th 2020 and is still recruiting participants as of October 8th 2022."
How many participants are recruited for this clinical experiment?
"Affirmative. Clinicaltrials.gov attests to this clinical trial's active recruitment, which began on September 28th 2020 and was last updated October 8th 2022; 15 participants are being sought at a single location."
Is Allogeneic adipose derived mesenchymal stem cell therapy a secure treatment option for individuals?
"Our team at Power rated Allogeneic adipose derived mesenchymal stem cells a 1 on the safety scale because it is in its initial clinical trial stage, with limited data to support both efficacy and harmlessness."
Share this study with friends
Copy Link
Messenger